How much funding has Isomorphic Labs raised?

Isomorphic Labs has raised $600M in total funding. Their latest funding round was Series A. Key investors include Thrive Capital; GV (Google Ventures); Alphabet Inc..

Where is Isomorphic Labs headquartered?

Isomorphic Labs is headquartered in London, United Kingdom. The company has a team of 201-500 people.

When was Isomorphic Labs founded?

Isomorphic Labs was founded in 2021. It is based in London, United Kingdom.

How much funding has Isomorphic Labs raised?

Isomorphic Labs has raised $600M in total funding. Key investors include Thrive Capital; GV (Google Ventures); Alphabet Inc..

Who is the CEO of Isomorphic Labs?

Sir Demis Hassabis is the CEO of Isomorphic Labs. The company was founded in 2021.

Where is Isomorphic Labs located?

Isomorphic Labs is headquartered in London, United Kingdom.

What funding stage is Isomorphic Labs at?

Isomorphic Labs is currently at the Growth Stage stage.

How many employees does Isomorphic Labs have?

Isomorphic Labs has approximately 201-500 employees.

Isomorphic Labs

Category: AI in Biotech / Drug Discovery

AI-first drug design and development company spun out of Google DeepMind, using frontier AI to reimagine drug discovery Isomorphic Labs was founded in 2021. The company is led by Sir Demis Hassabis. Based in London, United Kingdom. Team size: 201-500. Total funding raised: $600M. Latest round: Series A. Key investors include Thrive Capital; GV (Google Ventures); Alphabet Inc..

Founded: 2021
Headquarters: London, United Kingdom
Team size: 201-500
Total funding: $600M

Value proposition

Isomorphic Labs builds a unified AI drug design engine (IsoDDE) that predicts protein structures, binding affinities, and identifies novel drug targets with unprecedented accuracy, accelerating drug discovery from years to digital speed

Products and solutions

Isomorphic Labs Drug Design Engine (IsoDDE) — unified computational drug-design system; AlphaFold 3 (co-developed with Google DeepMind); Internal drug candidate pipeline focused on oncology and immunology; Dataverse (curated life science data infrastructure)

Unique value

Only AI drug discovery company with direct lineage to Nobel Prize-winning AlphaFold technology; unified multi-modality drug design engine that works across small molecules, biologics, and antibodies; backed by Alphabet/Google DeepMind with access to vast compute and talent

Target customer

Large pharmaceutical companies (Novartis, Eli Lilly, Johnson & Johnson); internal pipeline for oncology and immunology therapeutics

Industries served

Pharmaceutical drug discovery; Biotechnology; Oncology; Immunology; Therapeutics development

Technology advantage

IsoDDE more than doubles AlphaFold 3 accuracy on protein-ligand structure prediction; predicts binding affinities exceeding gold-standard physics-based methods at fraction of time/cost; identifies novel binding pockets from amino acid sequence alone; built on DeepMind's AlphaFold heritage with interdisciplinary team of ML researchers and drug discovery experts

How they differentiate

Direct lineage from Nobel Prize-winning AlphaFold technology; backed by Alphabet/Google DeepMind with unmatched compute resources; unified multi-modality drug design engine (small molecules, biologics, antibodies); interdisciplinary team combining world-class ML researchers with drug discovery experts; $3B+ in pharma partnership deal value before any clinical data

Main competitors

Recursion Pharmaceuticals; Insilico Medicine; Xaira Therapeutics; insitro; Schrödinger; Exscientia; Valo Health; Atomwise

Key partnerships

Novartis (strategic research collaboration, expanded Feb 2025, up to $1.2B in milestones); Eli Lilly (strategic research collaboration, up to $1.7B in milestones); Johnson & Johnson (multi-target cross-modality research collaboration, announced Feb 2025); Google DeepMind (parent/sister company, co-development of AlphaFold 3)

Notable customers

Novartis; Eli Lilly and Company; Johnson & Johnson

Major milestones

2021: Founded as Alphabet/DeepMind spinout; 2022: Opened Lausanne, Switzerland office; 2024: Partnered with Novartis & Eli Lilly ($3B combined deal value); 2024: Co-released AlphaFold 3; 2024: Nobel Prize in Chemistry awarded to Demis Hassabis & John Jumper for AlphaFold; 2025: Raised $600M Series A (first external funding) led by Thrive Capital; 2025: Expanded Novartis partnership; 2025: Partnered with Johnson & Johnson; 2026: Launched IsoDDE Drug Design Engine; 2026: In advanced talks to raise $2B+ Series B; 2026: First clinical trials expected by year-end

Growth metrics

Team grew from ~100 (2024) to ~340+ (2026); First clinical trials expected by end of 2026; Drug Design Engine (IsoDDE) launched Feb 2026; 3 major pharma partnerships signed (Novartis, Lilly, J&J)

Market positioning

Premium-tier AI drug discovery platform with strongest academic pedigree (Nobel Prize), largest compute infrastructure, and highest-value pharma partnerships. Positioned as the most ambitious AI-first drug discovery company with mission to "solve all disease"

Geographic focus

Global (HQ in London, UK; office in Lausanne, Switzerland; partnerships with global pharma companies)

Patents and IP

AlphaFold 3 (co-developed with Google DeepMind, released May 2024); Isomorphic Labs Drug Design Engine (IsoDDE, announced Feb 2026); Proprietary dataverse infrastructure; Multiple undisclosed patents related to AI drug design models

About Sir Demis Hassabis

Co-Founder & CEO of Google DeepMind (acquired by Google/Alphabet); Nobel Prize in Chemistry 2024 (AlphaFold); PhD in Cognitive Neuroscience from UCL; Founder of Elixir Studios; Former AI researcher at UCL Gatsby Unit; Chess master at age 13

Official website: https://www.isomorphiclabs.com